MONTREAL, Feb. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. com. Visit the TSX ETF Investor Centre to access our screener and comparison tool. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Message Board Total Posts: 4. Betteryear2. About Us | Theratechnologies Inc. " The 12-month stock price forecast is $18. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. MONTREAL, Nov. See a list of the most recent Stock Forum posts on Stockhouse. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ET. S. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. MONTREAL, Oct. Find the latest Theratechnologies Inc. Once expert advice is considered, the Company. Stockhouse. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. By continuing to use our service, you agree to our use of cookies. We also use them to share usage information with our partners. 65 per cent to C$1. European Headquarters. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View Company Info for Free. Theratechnologies . SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. 5%. A live webcast of Dr. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Forecast to breakeven in 2024 Jul 15. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Stockhouse. 25. Microsoft to invest $500M in Quebec AI economy. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. com. 5% workforce reduction. 4%. H. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. Website. The financial results presented in this press release are taken from the. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. 4. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. GUD | Complete Knight Therapeutics Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Headquarters. Real-time discussion about Theratechnologies Inc. . MONTREAL, Sept. The abstracts are now available at aacr. , alpha and beta) for all equities such as Theratechnologies. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. Theratechnologies Announces 1-for-4 Reverse Stock Split. Theratechnologies Inc. com uses cookies on this site. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Montreal-based biopharmaceutical company Theratechnologies Inc. com 10/16/2023. 17% from a day low at $1. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. VANCOUVER, British Columbia, Nov. Stockhouse. Senior Director, Investor Relations. Cookies are used to offer you a better browsing experience and to analyze our traffic. T. By continuing to use our service, you agree to our use of cookies. 9%, while the Biotechs industry saw earnings growing at 17. Theratechnologies Inc. 9 million as at August 31, 2023. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | July 20, 2023. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Cookies are used to offer you a better browsing experience and to analyze our traffic. The abstract and poster can be found on Theratechnologies’ website. Marsolais will present at the H. 04) earnings per share (EPS) for the quarter. Stockhouse. B2Gold Declares Fourth Quarter 2023 Dividend. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. Cookies are used to offer you a better browsing experience and to analyze our traffic. (NASDAQ:NASDAQ:THTX) Q1 2022 Earnings Conference Call April 13, 2022 8:30 AM ETCompany ParticipantsPaul Levesque - President & CEOPhilippe Dubuc - SVP &. 2% for this period. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. RESSOURCES. Theratechnologies had a negative net margin of 36. THTX | Complete Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. European Headquarters. Stockhouse. (THTX) NasdaqCM - NasdaqCM Real Time Price. com uses cookies on this site. 68 to a day high of $1. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Senior Director, Investor Relations. com uses cookies on this site. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. The firm offers its product under the brand name of. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. Market Cap. TH | October 13, 2022 - Q3 2022 Consolidated. $30. Theratechnologies Announces 1-for-4 Reverse Stock Split. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. By continuing to use our service, you agree to our use of cookies. Consensus forecasts updated Jul 21. MONTREAL, Feb. (2021-11-03 | TSX:TH) Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Stockhouse. 40 f102M H1. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. MONTREAL, March 07, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. Following the release, Knight will hold a conference call and audio webcast. Stockhouse. We also use them to share usage information with our partners. com uses cookies on this site. TH | September 5, 2023. T. Shares of Theratechnologies are up 4. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Theratechnologies will acquire all outstanding shares of Katana for US$5,300,000 or CA$6,900,000. 86 million for the quarter. Northwest also announces an update on its. 's motion for leave to commence. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 4% from the stock's current price. 66% compared to the previous year's 69. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. D. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 28 $1. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. Further. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. S. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. MONTREAL, Feb. The reported ($0. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 25 to $1. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. A high-level overview of Theratechnologies Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. GlobeNewswire. : Nasdaq Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. : Renegotiated Lease to Generate Substantial Annual Savings. View real-time stock prices and stock quotes for a full financial overview. The Theratechnologies Inc. The website address for Stockhouse has changed We changed the address of the Stockhouse website from to stockhouse. Trogarzo is a CD4-directed post-attachment HIV-1 inhibitor. It is the Company’s proprietary peptide linked to. com uses cookies on this site. Montréal, Québec, Canada . (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. Stockhouse. By continuing to use our service, you agree to our use of cookies. Theratechnologies is pepped up on peptides. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . com uses cookies on this site. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. Cookies are used to offer you a better browsing experience and to. Stockhouse. 617-356-1009. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. $30. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. Non-Profit & Charitable Organizations · United States · <25 Employees. communications@theratech. 4% annually. First Quarter Fiscal 2022 Financial Results. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. 71. L. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. MONTREAL, Feb. 33 +0. home message. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. . (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on. TH | February 28, 2023. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. 33. Company Description: Theratechnologies is pepped up on peptides. Stockhouse. During the last trading day the stock fluctuated 12. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. - October 10, 2023) - KO Gold Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. 08). By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc. com. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. MONTREAL, Aug. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. com uses cookies on this site. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. 11/05/2020 4:15:02 PM. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April. We also use them to share usage. Phone Number 15143319691. com uses cookies on this site. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Company Type For Profit. 1-514-336-7800. Theratechnologies Inc. 04) earnings per share (EPS) for the quarter. NEW YORK, Dec. Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. communications@theratech. - Q3 2022 North American Revenue Growth of 19%. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. October 13, 2022 07:30 ET | Source: Theratechnologies. 22M. 20% from a day low at $1. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 617-356-1009. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. THERATECHNOLOGIES INC. By continuing to use our service, you agree to our use of cookies. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. 514-336-7800. (2021-01-11 | TSX:TH) Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. com uses cookies on this site. Stockhouse. (Theratechnologies, or the Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal year 2022. By continuing to use our service, you agree to our use of cookies. 06 million, an increase of. T. 23 to a day high of $1. Stockhouse. View recently published Stock News reports from independent reports and journalists. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. GlobeNewswire. 2% to $21. We also use them to share usage. MONTREAL, Sept. Further. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. stock news by MarketWatch. Further. Stockhouse. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Stockhouse. com uses cookies on this site. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Trogarzo® and. . For investor inquiries: Leah Gibson. stock price gained 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. NCU. 02%. This news release constitutes a “designated news release” for the purposes of the. 46. Investor inquiries: Elif McDonald. By continuing to use our service, you agree to our use of cookies. Conjugating the short peptide with various anti-cancer agents allows for. 2. By continuing to use our service, you agree to our use of cookies. Learn why it. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. By continuing to use our service, you agree to our use of cookies. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Herein, we report. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 35 as of 10:41 a. Stockhouse. 9% more than in 2021. MONTREAL, Dec. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. BioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. com uses cookies on this site. Biopharmaceutical company Theratechnologies Inc. THTX earnings call for the period ending February 29, 2020. MONTREAL, Feb. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. Theratechnologies Inc. FY2023 revenue guidance range set between $90 million and $95 million. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. Shares of Theratechnologies are up 4. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Browse posts by Sector and Subsector. - Cash, bonds and money market funds of US$22. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 1. Top 173 largest Canadian Companies in the Drug Manufacturers—Specialty & Generic industry by Market Cap. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. Clinical-stage pharmaceutical company Theralase Technologies Inc. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Nov. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. View real-time stock prices and stock quotes for a full financial overview. The company was. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. m. La Bourse de Toronto a perdu. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 75%. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies’ R&D staff is bearing the brunt of. com uses cookies on this site. Theratechnologies Inc. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. (2013-04-03 | TSX:TH) Theratechnologies Inc. If you have HIV, it's important to know the difference. 24 million, 48. (THTX) stock. Stockhouse. (TH.